Azosemide

Research use only, not for human use.

Azosemide is a potent NKCC1 inhibitor (IC50s: 0.246?μM and 0.197?μM for hNKCC1A and NKCC1B).

Azosemide is a potent NKCC1 inhibitor (IC50s: 0.246?μM and 0.197?μM for hNKCC1A and NKCC1B).(In Vitro):Azosemide inhibits the sodium-potassium-chloride-cotransporter human variants hNKCC1B and hNKCC1A .(In Vivo):Azosemide shows a shorter terminal half-life (50.9% decrease) and MRT (64.1% decrease), smaller AUC (81.9% decrease), faster CL (454% increase), CLNR (307% increase) and CLR (853% increase) for NARs .

Azosemide inhibits the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B.

Azosemide shows a smaller AUC (81.9% decrease), shorter terminal half-life (50.9% decrease) and MRT (64.1% decrease), faster CL (454% increase), CLR (853% increase) and CLNR (307% increase) for NARs. Animal Model:Male Sprague-Dawley rats (control rats, weighing 310345 g) and NARs (weighing 220315 g) of 9 weeks of age Dosage:10 mg/kg (Pharmacokinetic Analysis) Administration:Infused over 1 min via the jugular vein (i.v.)Result:Showed a smaller AUC (81.9% decrease), shorter terminal half-life (50.9% decrease) and MRT (64.1% decrease), faster CL (454% increase), CLR (853% increase) and CLNR (307% increase) for NARs.

——

Others

Other Targets

——

——

——

27589-33-9

370.83

C12H11ClN6O2S2

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (674.15 mM)

NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl

——

(-20℃)

With Ice Pack

≥ 2 years